About BioLamina
BioLamina is a company based in Sundbyberg (Sweden) founded in 2008 by Magnus Kenneby and Kristian Tryggvason. BioLamina has raised $18.25 million across 4 funding rounds from investors including HHS, European Union and Bure Equity. BioLamina offers products and services including Biolaminin Matrices and Cell Therapy Grade Products. BioLamina operates in a competitive market with competitors including Abcam, BioLife Solutions, Stem Cell Technologies, Teknova and Meridian Bioscience, among others.
- Headquarter Sundbyberg, Sweden
- Founders Magnus Kenneby, Kristian Tryggvason
- SectorsHealthcare
- Email••••••••
- Website biolamina.com
- Social LinkedIn X Facebook
- Legal Name Biolamina Ab
- Total Equity Funding$18.25M (USD)
in 4 rounds
- InvestorsHHS
& 4 more
Products & Services of BioLamina
BioLamina offers a comprehensive portfolio of products and services, including Biolaminin Matrices and Cell Therapy Grade Products.
Matrices for expanding and differentiating human cells in research
Products for compliant stem cell processes and differentiation
Funding Insights of BioLamina
BioLamina has successfully raised a total of $18.25M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.25M
- Total Rounds 4
- First Round $331,582
(Aug 2009)
- Investors Count 5
All 4 funding rounds of BioLamina with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $23.58M | Debt – Conventional | – | – | European Investment Bank |
| Sep 2023 | $18.25M | Series B | – | Lauxera Capital Partners | |
| Apr 2021 | $444,281 | Grant | – | – | |
| Aug 2009 | $331,582 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in BioLamina
BioLamina has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, European Union and Bure Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on the healthcare sector | – | lauxera.com | Paris, France | |
Private equity firm focused on science, manufacturing, healthcare, and multiple sectors | 1992 | bure.se | Stockholm, Sweden | |
Growth investments in life science companies are managed by Northislet. | – | northislet.com | Stockholm, Sweden | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for BioLamina
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioLamina
32 people are tracked at BioLamina (8 in leadership, 6 in board & advisors, 18 in team).
| Name | Role | Group |
|---|---|---|
Magnus Kenneby | Co-Founder | Leadership |
Kristian Tryggvason | Co-Founder | Leadership |
Magnus Åkerhielm | CFO | Leadership |
Habib A M Sakil | Head Of Production | Leadership |
Therése Kallur | Chief Scientific Officer & VP, Business Development | Leadership |
Ulrika Ljungkvist | COO | Leadership |
Anders Lindblad | VP, Strategic Development | Leadership |
Malin Kele | Director Of Business Development | Leadership |
Jonas Pålsson | Board Member | Board & advisors |
Lotta Ljungqvist | Board Member | Board & advisors |
Sophie Hagströmer | Chairperson | Board & advisors |
Catarina Flyborg | Board Member | Board & advisors |
Alex Slack | Board Member | Board & advisors |
Max Jonson | Board Member | Board & advisors |
Meghana C. | Bioprocess Engineer | Team |
Emer Slowey | Bioprocess Engineer | Team |
Caijuan Zhan | Senior Scientist | Team |
Sara Malmstedt | Office Manager | Team |
Petra Edlund | Senior Scientist | Team |
Theresa Mader | Product Manager | Team |
12 more people are available in the full profile.
Complete people profiles for BioLamina
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioLamina
3 dated milestones of BioLamina across 18 years, from founding to its latest funding, stage changes and deals.
- Founded BioLamina is founded.
- Funding First funding round of $332K.
- Funding Latest funding round, Debt – Conventional,.
Competitors of BioLamina
BioLamina operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, BioLife Solutions, Stem Cell Technologies, Teknova and Meridian Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| biolifesolutions.com | 1987 | Bothell, United States | – | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| roosterbio.com | 2012 | Frederick, United States | $38.41M | 69 | Developer of human mesenchymal stem cells and extracellular vesicles | |
| bbisolutions.com | 1986 | Crumlin, United Kingdom | – | 301 | Kits and reagents are developed for life science research applications. | |
| duoningbio.com | 2005 | Shanghai, China | $14.88M | – | Serum-free cell culture media is supplied to biopharmaceutical industries. | |
| arunabio.com | 2017 | Athens, United States | $38.51M | – | Neural exosome platform is developed for neurodegenerative disease therapeutics. |
Detailed competitors of BioLamina
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioLamina
The website of BioLamina (biolamina.com) receives about 9.1K visits a month.
- Monthly visits9.1K
▲ 11.7% vs previous month
Websites whose visitors overlap most with BioLamina. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| celprogen.com | 100% | – | #3,394,353 | View details | |
| internationalstemcell.com | 100% | 2.6K | #7,053,485 | View details | |
nhnscr.org | nhnscr.org | 100% | – | – | – |
| lifelinecelltech.com | 100% | 9.2K | #2,327,277 | View details | |
allthingsstemcell.com | allthingsstemcell.com | 100% | – | #14,165,267 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for BioLamina
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Biolamina
Complete news archive for BioLamina
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to BioLamina
10 companies that operate in the same segment as BioLamina (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioLamina
BioLamina was founded in 2008 and raised its 1st funding round 1 year after it was founded.
BioLamina is headquartered in Sundbyberg, Sweden. It is registered at Sundbyberg, Stockholm County, Sweden.
BioLamina is a funded company, having raised a total of $18.25M across 4 funding rounds to date. The company's 1st funding round was a Grant of $331.58K, raised on Aug 2009.
BioLamina was founded in 2008 and is based in Sundbyberg, Sweden. Operations focus on the biotechnology sector, where full-length human recombinant laminins are manufactured for primary and stem-cell culture applications. The product portfolio encompasses matrices tailored for pluripotent stem cell maintenance, early epithelial development, and differentiation processes. Screening kits with various laminins are also offered to identify optimal matrices for specific cell types.
BioLamina's top competitors include Abcam, Meridian Bioscience and RoosterBio.
BioLamina offers Biolaminin Matrices and Cell Therapy Grade Products.
BioLamina has 5 investors. Key investors include HHS, European Union, Bure Equity, Lauxera Capital Partners, and Northislet.
BioLamina operates through Biolamina Ab.